Life Saving Stem Cell Therapy
Using Wharton-Jelly Mesenchymal Stem Cells
for Inflammatory Diseases
First Focus on Sepsis Induced Pathologies, ARDS and Septic Shock
1 DRUG 3 ACTIONS
StemInov is developing WhartSep, a large scale and off-the-shelf treatment.
WhartSep is the first drug candidate having 3 complementary actions to tackle the complex physiopathology of septic shock and ARDS
Unique advantages for a strong unmet medical need
THERAPEUTIC EFFECTIVENESS AND TOLERANCE OF FETAL SOURCE
NON LIMITED & NON INVASIVE SOURCING
SCALABLE & READY TO USE OFF THE SHELF PRODUCT
OUR TEAM
Ecole Centrale Lyon
Master EM Lyon
HEC Challenge + 2020-2
5y experience in Eurofins Genomics
Julie HUTIN
CEO & Co-founder
PU-PH - Head of Cellular Therapy Unit and Tissue Banking, Cord Blood Banking (UTCT)
Head of a CNRS Team
Lead to the patent operated by StemInov
70 Publications in ATMP over the last 12 yrs
Danièle BENSOUSSAN
CSO & Co-founder
Eric is a serial entrepreneur who combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. He is the CEO of PDC line Pharma
Eric HALIOUA
Strategy
Prof. in an Intensive Care Unit of a University Hospital. In charge of designing and conducting experimental and translational research towards sepsis
PE CHARLES
Clinical Strategy
Industrial Pharmacist
Cell Production GMP Unit Expert
CMC expert in cell and gene therapy
Several GMP accreditations
Claude DEDRY
CMC
Expert in regulatory affair with experience in ATMP
Intellectual Property management
Roland GORDON BERESFORD
Regulatory
